We thus assessed the sensitivity of 8 different RTK inhibitors (RTKis)—afatinib (AFA), dacomitinib (DAC), erlotinib (ERL), gefitinib (GEF), lapatinib (LAP), neratinib (NER), sunitinib (SUN), and vandetanib (VAN)—against 3 different AR-positive PCa cell lines: LNCaP, LAPC-4, and 22Rv1 cells. Here, AR is linked to posterior cortical atrophy.